Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail aims to wipe out hidden leukemia cells

NCT ID NCT05168930

Recruiting now Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether combining zanubrutinib and venetoclax can clear even trace amounts of cancer in people with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study enrolls 45 adults whose disease has returned after at least one prior treatment. Participants take both drugs daily for up to 15 cycles, and researchers will measure how many achieve undetectable minimal residual disease (uMRD) — meaning no cancer cells can be found by sensitive tests.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
zanubrutinib and venetoclax (drugs)
What this could lead to
If successful, this combination could offer a more effective, chemotherapy-free option for people with relapsed CLL/SLL, potentially achieving deep remission without detectable cancer cells.
What could go wrong
This is a small, early-phase (phase 2) trial with only 45 participants, so results may not apply to everyone. Side effects from the drugs are possible, and the combination may not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) SMALL LYMPHOCYTIC LYMPHOMA (SLL)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beth Israel Deaconess Medical Center

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact

    Contact

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact

    Contact

  • New England Cancer Specialists

    RECRUITING

    Scarborough, Maine, 04074, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • South Shore Hospital

    RECRUITING

    South Weymouth, Massachusetts, 02190, United States

    Contact

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.